Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
Active, not recruiting · Phase 3 · NCT04838444
Conditions: Chikungunya Virus Infection
At a glance
- Research payments reported, 2025
- $3,044
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 363
About the trial
- Sponsor
- Valneva Austria GmbH
- Tested
- VLA1553 (biological)
- Dates
- Started 2021-04-02; completion 2031-05
- Results posted
- Yes
In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).
From ClinicalTrials.gov, last updated 2026-07-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Valneva Austria GmbH reported $3,044 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- William B. Smith, M.D. Specialist · New Orleans, LA
- Adam B. Brosz, M.D. Family Medicine · Grand Island, NE
- Brandon J. Essink, M.D. Family Medicine · Creighton, NE
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Amr - Knoxville - Volunteer Research Group $2,639
- Meridian Clinical Research - Grand Island $360
- Meridian Clinical Research - Corporate Headquarters $45
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.